AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Freckle count
Number of subjects: 351
Study 10380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Mole count
Number of subjects: 351
Study 10380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Working as a farmer
Number of subjects: 351
Study 10380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of sunscreens
Number of subjects: 351
Study 8983399 — intervention group
Group type: EXPERIMENTAL
Intervention: Epristeride 5 mg oral dose
Number of subjects: 12
Study 8983399 — intervention group
Group type: EXPERIMENTAL
Intervention: Epristeride 4.5 mg intravenous infusion
Number of subjects: 12
Study 8983399 — intervention group
Group type: COMPARATOR
Intervention: Epristeride 5 mg oral dose and 4.5 mg intravenous infusion
Number of subjects: 12
Study 1750594 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (double-blind, placebo-controlled)
Number of subjects: 2
Study 1750594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (patient-controlled analgesia)
Number of subjects: 2
Study 1750594 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (open administration)
Number of subjects: 2
Study 1750594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 6174719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron therapy for 6 to 8 days
Number of subjects: 68
Study 6174719 — intervention group
Group type: COMPARATOR
Intervention: Nonanemic infants (control group)
Number of subjects: 68
Study 31402114 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (100 mg at weeks 0 and 4 then every 8 weeks)
Number of subjects: 1048
Study 31402114 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab (300 mg at weeks 0, 1, 2, 3, and 4, then every 4 weeks)
Number of subjects: 1048
Study 31402114 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 1048
Study 31402114 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab
Number of subjects: 1048
Study 31402114 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab and Secukinumab
Number of subjects: 1048
Study 28674348 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg) in EAC group
Number of subjects: 200
Study 28674348 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole (10 mg) in RAC group
Number of subjects: 200
Study 28674348 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EAC and RAC regimens
Number of subjects: 200
Study 26386993 — intervention group
Group type: EXPERIMENTAL
Intervention: COSS (conversation roadmap, monitoring of cooperation, extra occupational physician support)
Number of subjects: 64
Study 26386993 — intervention group
Group type: COMPARATOR
Intervention: Common practice
Number of subjects: 64
Study 24977401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual alprazolam (0.5 mg)
Number of subjects: 220
Study 24977401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alprazolam (0.5 mg)
Number of subjects: 220
Study 22545364 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone ointment (twice a day)
Number of subjects: 30
Study 22545364 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atorvastatin (20 mg daily)
Number of subjects: 30
Study 22545364 — intervention group
Group type: COMPARATOR
Intervention: Placebo atorvastatin tablet (daily)
Number of subjects: 30
Study 22545364 — intervention group
Group type: COMPARATOR
Intervention: Placebo triamcinolone ointment (twice a day)
Number of subjects: 30
Study 21535498 — intervention group
Group type: COMPARATOR
Intervention: White Bread (WB) 57 g, 160 cal, 1 g fiber
Number of subjects: 13
Study 21535498 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw Cranberries (RC) 55 g, 21 cal, 1 g fiber
Number of subjects: 13
Study 21535498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetened Dried Cranberries (SDC) 40 g, 138 cal, 2.1 g fiber
Number of subjects: 13
Study 21535498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetened Dried Cranberries with Less Sugar (SDC‐LS) 40 g, 113 cal, 1.8 g fiber + 10 g polydextrose
Number of subjects: 13
Study 21535498 — intervention group
Group type: COMPARATOR
Intervention: White Bread (WB)
Number of subjects: 13
Study 21535498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetened Dried Cranberries (SDC)
Number of subjects: 13
Study 21535498 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw Cranberries (RC)
Number of subjects: 13
Study 21535498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetened Dried Cranberries with Less Sugar (SDC‐LS)
Number of subjects: 13
Study 21535498 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw Cranberries (RC) and Sweetened Dried Cranberries with Less Sugar (SDC‐LS)
Number of subjects: 13
Study 17606812 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 1775
Study 16051497 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled doses of computer work involving prolonged static posture
Number of subjects: 0
Study 16051497 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled doses of computer work involving increased typing speed
Number of subjects: 0
Study 16051497 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled doses of computer work involving increased typing force
Number of subjects: 0
Study 16051497 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified in detail)
Number of subjects: 0
Study 11940749 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 10
Study 11940749 — intervention group
Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation plus Pressure Support (SIMV-PS)
Number of subjects: 10
Study 10076111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of normal saline solution
Number of subjects: 110
Study 10076111 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected music
Number of subjects: 110
Study 10076111 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 1550777 — intervention group
Group type: EXPERIMENTAL
Intervention: VMBCP
Number of subjects: 91
Study 1550777 — intervention group
Group type: COMPARATOR
Intervention: VAD
Number of subjects: 91
Study 2864073 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (0.15 mg/kg/5 min iv)
Number of subjects: 0
Study 2864073 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (0.3 mg/kg/5 min iv)
Number of subjects: 0
Study 2864073 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (0.1 mg/kg/5 min)
Number of subjects: 0
Study 2864073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31391682 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorophytum borivilianum (CB) 3 g/day
Number of subjects: 60
Study 29688826 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation of affected sinus ostia
Number of subjects: 0
Study 29688826 — intervention group
Group type: COMPARATOR
Intervention: Balloon dilation in the nasal cavity (placebo)
Number of subjects: 0
Study 26965722 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block (group E&G) with continuous epidural and general anaesthesia, using ropivacaine for intraoperative and postoperative blocks.
Number of subjects: 70
Study 26965722 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia only (group G) with remifentanil for analgesia.
Number of subjects: 70
Study 26043363 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D camera system
Number of subjects: 2
Study 26043363 — intervention group
Group type: COMPARATOR
Intervention: 2-D camera system
Number of subjects: 2
Study 23673093 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with blood cultures before antibiotics protocol
Number of subjects: 0
Study 23673093 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with ≥5 protocols in the 6-hour resuscitation bundle
Number of subjects: 0
Study 23673093 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance during 6-hr resuscitation and 24-hour management bundles
Number of subjects: 0
Study 21599820 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) and stavudine (d4T)
Number of subjects: 911
Study 21599820 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LA/SHL)
Number of subjects: 911
Study 18843436 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g daily
Number of subjects: 125
Study 18843436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 17175635 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine treatment (0.4 g x kg(-1) x d(-1) orally for 7 days)
Number of subjects: 86
Study 17175635 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tyrosine)
Number of subjects: 86
Study 17175635 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine treatment and Placebo
Number of subjects: 86
Study 12636896 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) in ICU
Number of subjects: 466
Study 12636896 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) in ward
Number of subjects: 466
Study 10612763 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting
Number of subjects: 132
Study 10612763 — intervention group
Group type: COMPARATOR
Intervention: Continuous open incision
Number of subjects: 132
Study 10219183 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive oral protocol consisting of elimination of bacterial plaque, mouthwash with chlorhexidine 0.12%, topical application of iodopovidone, and nystatin 500,000 units.
Number of subjects: 96
Study 10219183 — intervention group
Group type: COMPARATOR
Intervention: Palliative treatment for complications (Group I).
Number of subjects: 96
Study 7942575 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Aerobic exercise (DA)
Number of subjects: 24
Study 7942575 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Resistance exercise (DR)
Number of subjects: 24
Study 3359824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage with 200 ml of 25 degrees C normal saline solution
Number of subjects: 27
Study 3359824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage with 200 ml of 37 degrees C normal saline solution
Number of subjects: 27
Study 3359824 — intervention group
Group type: COMPARATOR
Intervention: Routine bronchoscopic examination
Number of subjects: 27
Study 29627188 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of black mothers
Number of subjects: 420
Study 29627188 — intervention group
Group type: COMPARATOR
Intervention: Maternal race (black)
Number of subjects: 420
Study 29627188 — intervention group
Group type: COMPARATOR
Intervention: Breast milk diet
Number of subjects: 420
Study 29627188 — intervention group
Group type: COMPARATOR
Intervention: Public insurance status
Number of subjects: 420
Study 29627188 — intervention group
Group type: COMPARATOR
Intervention: Bronchopulmonary dysplasia
Number of subjects: 420
Study 29200983 — intervention group
Group type: EXPERIMENTAL
Intervention: PROHIGH (2.9 g.kg‐1.d‐1)
Number of subjects: 14
Study 29200983 — intervention group
Group type: COMPARATOR
Intervention: PROMOD (1.8 g.kg‐1.d‐1)
Number of subjects: 14
Study 25689594 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV/CI guided group (target PPV <12%, CI >2.5 L/min/m², MAP >70 mmHg)
Number of subjects: 31
Study 25689594 — intervention group
Group type: COMPARATOR
Intervention: MAP-guided group (target MAP >70 mmHg)
Number of subjects: 31
Study 25689594 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV/CI group
Number of subjects: 31
Study 25689594 — intervention group
Group type: COMPARATOR
Intervention: MAP-guided group
Number of subjects: 31
Study 23517178 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine (48 mg)
Number of subjects: 16
Study 23517178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20627917 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic positive airway pressure (APAP) titration
Number of subjects: 249
Study 20627917 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory APAP titration
Number of subjects: 249
Study 20627917 — intervention group
Group type: COMPARATOR
Intervention: Manual titration
Number of subjects: 249
Study 20627917 — intervention group
Group type: COMPARATOR
Intervention: Home APAP titration
Number of subjects: 249
Study 19108595 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and deep sedation (MAC) using ketamine-midazolam-propofol anesthetic combination
Number of subjects: 100
Study 19108595 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and deep sedation (MAC)
Number of subjects: 100
Study 16618562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine extended release (TER) 4 mg once daily 4 hours or less before bed
Number of subjects: 850
Study 16618562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study 12810615 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (4 weeks duration)
Number of subjects: 35
Study 12810615 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 35
Study 12810615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 35
Study 10782908 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (1 g-0.2 g every 8 h intravenously, then 500 mg-125 mg every 8 h orally)
Number of subjects: 96
Study 10782908 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (1 g every 6 h intravenously)
Number of subjects: 96
Study 10782908 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (for patients on prophylactic norfloxacin)
Number of subjects: 96
Study 10782908 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (for patients on prophylactic norfloxacin)
Number of subjects: 96
Study 10782908 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 96
Study 8794600 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate consumption
Number of subjects: 3971
Study 8794600 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 3971
Study 8794600 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy
Number of subjects: 3971
Study 1428550 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal Nerve Fiber Layer Defects (RNFL)
Number of subjects: 28
Study 1428550 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit defects
Number of subjects: 28
Study 1428550 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge defects
Number of subjects: 28
Study 1428550 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse defects
Number of subjects: 28
Study 1428550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed defects
Number of subjects: 28
Study 1428550 — intervention group
Group type: EXPERIMENTAL
Intervention: Location of defects
Number of subjects: 28
Study 2870124 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol (600 mg/day)
Number of subjects: 0
Study 2870124 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (300 mg/day)
Number of subjects: 0
Study 2870124 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg/day)
Number of subjects: 0
Study 30690288 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Warning Score‐guided proactive rapid response team model
Number of subjects: 12148
Study 30690288 — intervention group
Group type: COMPARATOR
Intervention: Rapid response team model based on staff nurse identification of vital sign derangements
Number of subjects: 12148
Study 30091135 — intervention group
Group type: EXPERIMENTAL
Intervention: Education workshops (Group E1)
Number of subjects: 201
Study 30091135 — intervention group
Group type: COMPARATOR
Intervention: Standard information and medical service (Group E0)
Number of subjects: 201
Study 27618445 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed vegetation
Number of subjects: 0
Study 27618445 — intervention group
Group type: EXPERIMENTAL
Intervention: Other landcover categories
Number of subjects: 0
Study 27618445 — intervention group
Group type: EXPERIMENTAL
Intervention: Landcover refuges under future climate change
Number of subjects: 0
Study 25245812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 181
Study 25245812 — intervention group
Group type: COMPARATOR
Intervention: IFNβ-1a IM (30 mg weekly)
Number of subjects: 181
Study 25245812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 22115802 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamp Crushing Technique (CRUSH)
Number of subjects: 60
Study 22115802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection (CUSA)
Number of subjects: 60
Study 22115802 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar device (LigaSure)
Number of subjects: 60
Study 20199265 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment of femoropopliteal arteries
Number of subjects: 58
Study 17531400 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Number of subjects: 258
Study 17531400 — intervention group
Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 258
Study 16366809 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined family and school intervention condition
Number of subjects: 36
Study 16366809 — intervention group
Group type: EXPERIMENTAL
Intervention: School-only condition
Number of subjects: 36
Study 16366809 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study 11982840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (10 microg x kg(‐1)) with 0.5% tetracaine D10 (hyperbaric morphine group)
Number of subjects: 14
Study 11982840 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine mixed with saline after 0.5% tetracaine D10 (hypobaric morphine group)
Number of subjects: 14
Study 10436095 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CT changes identified by experienced stroke specialists and other physicians
Number of subjects: 70
Study 9002910 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2137972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 82
Study 2137972 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 82
Study 714380 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-releasing artificial tears (SR-AT)
Number of subjects: 40
Study 31365151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/everolimus
Number of subjects: 60
Study 31365151 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus/mycophenolate
Number of subjects: 60
Study 27793063 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation (ES) strength training in the morning (MTG, 07:00-08:00 h)
Number of subjects: 20
Study 27793063 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation (ES) strength training in the evening (ETG, 17:00-18:00 h)
Number of subjects: 20
Study 27793063 — intervention group
Group type: COMPARATOR
Intervention: Both groups (MTG and ETG)
Number of subjects: 20
Study 25241106 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 42
Study 25241106 — intervention group
Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 42
Study 25241106 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surfactants
Number of subjects: 42
Study 23351224 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home bleaching
Number of subjects: 96
Study 23351224 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically activated office bleaching
Number of subjects: 96
Study 23351224 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP laser‐activated office bleaching
Number of subjects: 96
Study 23351224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bleaching)
Number of subjects: 96
Study 21723164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 16
Study 21723164 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 16
Study 21352172 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Preventive Intervention (SPI)
Number of subjects: 0
Study 21352172 — intervention group
Group type: COMPARATOR
Intervention: Needs‐Based Intervention (NBI)
Number of subjects: 0
Study 16490430 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone monotherapy at 4 mg/day for 3 months
Number of subjects: 30
Study 16490430 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with rosiglitazone at 4 mg/day and atorvastatin at 10 mg/day for 3 months
Number of subjects: 30
Study 12969088 — intervention group
Group type: EXPERIMENTAL
Intervention: L30AC (twice‐daily 30 mg lansoprazole, 1000 mg amoxicillin and 500 mg clarithromycin for 7 days)
Number of subjects: 800
Study 12969088 — intervention group
Group type: EXPERIMENTAL
Intervention: L15AC (twice‐daily 15 mg lansoprazole, 1000 mg amoxicillin and 500 mg clarithromycin for 7 days)
Number of subjects: 800
Study 12969088 — intervention group
Group type: COMPARATOR
Intervention: LP (once‐daily 15 mg lansoprazole for 14 days)
Number of subjects: 800
Study 12969088 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 800
Study 11038044 — intervention group
Group type: COMPARATOR
Intervention: LV5FU2 regimen (leucovorin 100 mg/m2 + 5-FU 400 mg/m2 bolus + 5-FU 600 mg/m2 infusion)
Number of subjects: 102
Study 11038044 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2 + CPT-11 regimen (CPT-11 at 180 mg/m2 on day 1 before LV5FU2)
Number of subjects: 102
Study 11038044 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2 + CPT-11 regimen
Number of subjects: 102
Study 9254959 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1587191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 515
Study 1587191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 515
Study 1587191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study 3888594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine and pirenzepine (group A)
Number of subjects: 125